US Patent Issued to CULLGEN (SHANGHAI) on Sept. 9 for "Tropomyosin receptor kinase (TRK) degradation compounds and methods of use" (American, Chinese Inventors)

ALEXANDRIA, Va., Sept. 10 -- United States Patent no. 12,410,171, issued on Sept. 9, was assigned to CULLGEN (SHANGHAI) INC. (Shanghai).

"Tropomyosin receptor kinase (TRK) degradation compounds and methods of use" was invented by Jing Liu (Oradell, N.J.), Jialiang Wang (Nashville, Tenn.), Xiaoran Han (Shanghai), Liqun Chen (Shanghai) and Chengwei Zhang (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "This disclosure relates to bivalent compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the bivalent compounds, and to methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to metho...